Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.

DRUG

Goserelin

Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.

DRUG

Bicalutamide

On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.

Trial Locations (33)

15706

Hospital Santiago de Compostela, Santiago de Compostela

22399

Urologische Gemeinschaftspraxis, Hamburg

28034

Hospital universitario Ramón y Cajal, Madrid

28040

Hospital Clinico Universitario S. Carlos, Madrid

28222

Hospital Universitario Puerta de Hierro, Majadahonda, Madrid

28805

Hospital Universitario Principe de Asturias, Alcalá de Henares-Madrid

28922

Fundacion Hospital Alcorcón, Alcorcón

33006

Hospital Universitario Central de Asturias, Oviedo

36204

Hospital Xeral de Vigo, Vigo

41014

Hospital Virgen Macarena, Seville

42103

Wuppertaler Gemeinschaftspraxis, Wuppertal

46325

Gemeinschaftspraxis, Borken

48013

Hospital de Basurto, Bilbao (Bizkaia)

50667

Gemeinschaftspraxis, Cologne

63069

Klinikum Offenbach GmbH, Offenbach

82152

Urologische Klinik Planegg, Planegg

90763

Euromed Clinic, Fürth

96047

Facharztpraxis für Urologie, Bamberg

01307

Universitätsklinikum Dresden, Dresden

04109

VITURO Gesellschaft für Klinische Studien, Leipzig

Unknown

Complejo Hospitalario Universitario A Coruña, A Coruña

08025

Fundación Puigvert, Barcelona

07500

Hospital Manacor, Manacor

BS2 8HW

United Bristol Healthcare NHSTrust Bristol Royal Infirmary, Bristol

FK1 5QE

Falkirk and District Royal Infirmary, Falkirk

G51 4TF

Southern General Hospital, Glasgow

HU16 5JQ

Castle Hill Hospital, Hull

E11 1NR

Whipps Cross University Hospital, London

NW3 2QG

The Royal Free Hospital, London

SE5 9RS

King's College Hospital, London

PL6 8DH

Derriford Hospital, Plymouth

S10 2JF

Royal Hallamshire Hospital, Sheffield South, Sheffield

SR4 7TP

Sunderland Royal Hospital, Sunderland

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY